Innoviva Inc (NASDAQ:INVA) shares were up 7.1% during mid-day trading on Thursday . The company traded as high as $14.96 and last traded at $14.94. Approximately 1,249,328 shares traded hands during trading, an increase of 13% from the average daily volume of 1,104,149 shares. The stock had previously closed at $13.95.
INVA has been the topic of a number of analyst reports. Zacks Investment Research downgraded shares of Innoviva from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. BidaskClub downgraded shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 2nd. Finally, ValuEngine downgraded shares of Innoviva from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th.
The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 4.23 and a beta of 1.82. The company has a debt-to-equity ratio of 2.41, a quick ratio of 34.92 and a current ratio of 34.92.
Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.05). The firm had revenue of $55.18 million during the quarter. Innoviva had a net margin of 151.36% and a negative return on equity of 508.18%. Equities research analysts expect that Innoviva Inc will post 1.46 EPS for the current year.
In other news, insider Geoffrey Hulme purchased 7,000 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The shares were acquired at an average cost of $14.80 per share, for a total transaction of $103,600.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director George Bickerstaff purchased 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The stock was purchased at an average price of $15.90 per share, for a total transaction of $238,500.00. The disclosure for this purchase can be found here. Insiders purchased a total of 32,000 shares of company stock worth $491,100 over the last quarter. 0.18% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. TrimTabs Asset Management LLC bought a new stake in Innoviva during the 4th quarter worth approximately $1,116,000. Amalgamated Bank bought a new stake in Innoviva during the 4th quarter worth approximately $194,000. Assenagon Asset Management S.A. bought a new stake in Innoviva during the 4th quarter worth approximately $3,447,000. Financial Gravity Companies Inc. bought a new stake in Innoviva during the 4th quarter worth approximately $40,000. Finally, Geode Capital Management LLC increased its stake in Innoviva by 3.0% during the 4th quarter. Geode Capital Management LLC now owns 799,879 shares of the biotechnology company’s stock worth $13,957,000 after purchasing an additional 23,141 shares in the last quarter. 79.00% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Macon Daily and is owned by of Macon Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://macondaily.com/2019/05/02/innoviva-inva-trading-up-7-1.html.
About Innoviva (NASDAQ:INVA)
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
Read More: Is it Safe to Invest in Commodities?
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.